Benzinga - by Vandana Singh, Benzinga Editor.
Orthopedic medical device company Treace Medical Concepts Inc (NASDAQ:TMCI) on Tuesday reported a first-quarter EPS loss of $(0.30), down from $(0.23) a year ago, better than the consensus of $(0.31).
The company reported sales of $51.11 million, up 21%, beating the consensus of $49.1 million.
The increase was driven by a higher volume of procedure kits sold due to an expanded surgeon customer base and a product mix shift that resulted from increased adoption of newer technologies and increased sales of complementary products used in bunion and related midfoot procedures.
Guidance: Treace Medical Concepts cut its fiscal year 2024 sales guidance to $201 million-$211 million, down from a prior guidance of $220 million-$225 million.
The company anticipates adjusted EBITDA to improve approximately 50% compared to full-year 2023.
Analyst Reaction:
Stifel downgrades Treace Medical Concepts from Buy to Hold and lowers the price target from $15 to $6, noting multiple increasing competitive headwinds that have added incremental uncertainty to the company’s near-to-long-term outlook.
- Treace’s commercial performance has suffered due to competition from imitation Lapiplasty products and rival minimally-invasive osteotomy offerings. The company faces intense competition, particularly in the osteotomy segment.
- While Treace’s Lapiplasty remains strong in Lapidus Fusion procedures, which comprise a smaller portion of bunion corrections, it lacks an osteotomy product for the more prevalent bunion correction procedures.
- Management has hinted at launching an osteotomy product by the end of 2024, recognizing the necessity for a more comprehensive product portfolio.
- Truist writes that this is the second major guidance cut in 7 months, which raises incremental uncertainty about the predictability of the business model.
- The competitive factors behind this reduction feel more structural than the (seemingly) more transient seasonality-related items.
JP Morgan downgrades Treace Medical from Overweight to Neutral and lowers the price target from $15 to $8.
UBS maintains Treace Medical Concepts with a Buy, lowering the price target from $17 to $16.
Price Action: TMCI shares are down 62.6% at $4.161 at last check Wednesday.
Photo via Shutterstock
Latest Ratings for TMCI
| Mar 2022 | Morgan Stanley | Maintains | Overweight | |
| Mar 2022 | Stifel | Maintains | Buy | |
| Jan 2022 | Morgan Stanley | Upgrades | Equal-Weight | Overweight |
View the Latest Analyst Ratings
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.